RecruitingNot ApplicableNCT07019519

POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS

Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS

Sponsor

University of Copenhagen

Enrollment

30 participants

Start Date

Mar 15, 2025

Study Type

INTERVENTIONAL

Conditions

Healthy Postural Orthostatic Tachycardia Syndrome (POTS)

Summary

This study will describe the interplay between the gut hormones GIP and CCK and their regulation of blood flow to the large vessels in patients with Postural Orthostatic Tachycardia Syndrome (POTS) and GIP, CCK and GLP-1 in healthy. This is addressed by hormone infusions during MR-scans of the abdomen and intake of oral glucose.

Eligibility

Min Age: 18 YearsMax Age: 50 Years

Inclusion Criteria8

Previously diagnosed with POTS in tilt test or active stand-test (either newly diagnosed within last 3 months or in new tilt test/active stand test during screenings visit)
Reproducible orthostatic intolerance with raise in HR on >30 bpm when standing within 10 minutes of change of supine to standing in age >19 years or >40 bpm in age 18-19 years.
POTS symptoms/orthostatic intolerance
Age 18-50
Waist ratio <180 cm
Age 18-50
Waist ratio <180 cm
Matched a POTS patient in age, sex and BMI

Exclusion Criteria20

Chronic illness
Metallic implants
Above 10 alcoholic drinks or week or substance abuse
Other types of sinus tachycardia or heart disease
Liverenzymes two times above normal values
Decreased kidney function eGFR <90 or elevated kreatinkinasis
Thyroid disease or TSH out of reference
Uncontrollable low or high blood pressure
Blood vessels that cannot be visualized on MR
Any disease that might influence the health of the participant during the study or participants that receives medicine that cannot be paused for 36 hours
Chronic illness
Metallic implants
Above 10 alcoholic drinks or week or substance abuse
POTS; other types of sinus tachycardia or heart disease
Liverenzymes two times above normal values
Decreased kidney function eGFR <90 or elevated kreatinkinasis
Thyroid disease or TSH out of reference
Uncontrollable low or high blood pressure, Orthostatic hypotension
Blood vessels that cannot be visualized on MR
Any disease that might influence the health of the participant during the study or participants that receives medicine that cannot be paused for 36 hours

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSaline/Placebo

NaCl(9mg/ml)

OTHERGIPR antagonist

GIP(3-30)NH2

OTHERGLP-1R antagonist

GLP-1(9-39)NH2

OTHERCCK agonist

CCK-8

Locations(1)

Rigshospitalet

Copenhagen, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07019519

Related Trials

Study of New Magnetic Resonance Imaging Methods of the Brain

NCT000045771 location

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

NCT071696301 location